Next-Generation Biparatopic Nanobody Targeting ALB and CD40 for Cancer Therapy

VHH-P660 is a novel humanized nanobody-based biparatopic protein, currently at the Biological Testing stage, developed for cancer therapy. It is specifically engineered to target both albumin (ALB) and CD40 molecule (CD40), two key proteins with significant roles in tumor biology and immune modulation. Designed with precision, VHH-P660 combines a single-domain antibody against albumin with dual single-chain variable fragments targeting CD40, offering promise for enhanced tumor targeting, improved pharmacokinetics, and potent immunomodulatory effects. This innovative modality is positioned to address significant challenges in current cancer treatment paradigms.

Licensing Opportunity

VHH-P660 is available for out-licensing and collaborative development opportunities. We welcome inquiries from partners interested in advancing this innovative cancer immunotherapy platform.

Development Phase

Modality

VHH-P660 employs a biparatopic design, comprising a nanobody (single-domain antibody) that binds human serum albumin fused in tandem with two single-chain variable fragments that specifically recognize CD40. The nanobody structure provides notable advantages such as small molecular size, high tissue penetration, robust stability, and ease of manufacturing. This format facilitates both efficient tumor localization, via albumin binding for extended half-life, and potent immune engagement through CD40 modulation. These combined structural attributes enable VHH-P660 to access solid tumor environments where larger antibodies may be less effective, potentially translating to improved therapeutic efficacy in cancer.

Target

ALB and CD40 are pivotal molecular targets with distinct yet complementary roles in cancer biology. ALB, a major plasma protein, is central to maintaining oncotic pressure and is widely distributed in the circulatory system. It is exploited by therapeutic agents for enhanced systemic distribution and increased half-life due to its abundance and long circulation time. CD40, a member of the tumor necrosis factor receptor superfamily, is primarily expressed on antigen-presenting cells and certain tumor cells, orchestrating immune cell activation and anti-tumor responses. Targeting ALB improves bioavailability and pharmacokinetics of nanobody-based therapeutics, while concurrent targeting of CD40 offers strategic immunomodulation. VHH-P660’s dual specificity for ALB and CD40 provides it with the strategic value to combine optimal distribution with direct immune activation, positioning it as a promising therapeutic candidate in cancer treatment.

Mechanism of Action

VHH-P660 exerts its anti-cancer effects via dual mechanisms. By binding ALB, it leverages albumin’s naturally high abundance to enhance systemic stability and tissue distribution, optimizing pharmacokinetic exposure. Simultaneously, the tandem single-chain variable fragments specifically engage CD40, a critical signal transducer on antigen-presenting cells, modulating immune activation pathways and promoting adaptive anti-tumor immunity. This dual-targeting strategy enables VHH-P660 to function both as a signal transduction modulator and a carrier for extended bioavailability. The nanobody platform underlying VHH-P660 offers great versatility for further development into advanced biotherapeutics such as antibody-drug conjugates or multispecific constructs, expanding its potential clinical applications in oncology.

Cancer

Cancer comprises a broad group of diseases characterized by the uncontrolled growth and spread of abnormal cells, representing a leading cause of mortality globally. Numerous forms—such as lung, breast, colorectal, and hematological cancers—impose a significant public health and socioeconomic burden. Current standard-of-care treatments include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapies. Despite these advances, many patients face drug resistance, immune evasion, severe side effects, and disease relapse, underscoring a persistent need for novel, more effective, and tolerable therapies. The advent of antibody-based modalities and immune checkpoint modulation has improved outcomes, but limitations remain, particularly in solid tumors with challenging microenvironments. VHH-P660’s dual targeting of ALB and CD40 is poised to address unmet needs by combining optimized pharmacokinetics with the activation of anti-tumor immune responses, presenting a compelling new approach within the cancer therapeutic landscape.